Abstract
The combination of two nucleoside analogues, didanosine (2',3'- dideoxyinosine or ddI) and stavudine (2',3'-didehydro-2',3'-dideoxythymidine or d4T) was studied in a double-blind dose-ranging trial to provide information about toxicity and efficacy. The 86 patients studied were antiretroviral naive and had pretreatment CD4 cell counts between 200 and 500 cells/mm3. The combination was well tolerated, with no evidence of dose- related side effects and mini- real development of peripheral neuropathy. There was a sustained decrease in human immunodeficiency virus (HIV) viral RNA levels, which appeared greater in patients receiving a full dose of one or both compounds. A concomitant increase in CD4 cell numbers, which was sustained over 52 weeks of follow-up and which was also dose related, was observed. This combination therapy deserves further study, particularly as part of triple-drug regimens.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 89-93 |
| Number of pages | 5 |
| Journal | Antiviral Therapy |
| Volume | 2 |
| Issue number | SUPPL.3 |
| State | Published - 1997 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
Cite this
Randomized double-blind study of combination therapy with didanosine and stavudine in HIV-infected individuals. / Pollard, Richard B.
In: Antiviral Therapy, Vol. 2, No. SUPPL.3, 1997, p. 89-93.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Randomized double-blind study of combination therapy with didanosine and stavudine in HIV-infected individuals
AU - Pollard, Richard B
PY - 1997
Y1 - 1997
N2 - The combination of two nucleoside analogues, didanosine (2',3'- dideoxyinosine or ddI) and stavudine (2',3'-didehydro-2',3'-dideoxythymidine or d4T) was studied in a double-blind dose-ranging trial to provide information about toxicity and efficacy. The 86 patients studied were antiretroviral naive and had pretreatment CD4 cell counts between 200 and 500 cells/mm3. The combination was well tolerated, with no evidence of dose- related side effects and mini- real development of peripheral neuropathy. There was a sustained decrease in human immunodeficiency virus (HIV) viral RNA levels, which appeared greater in patients receiving a full dose of one or both compounds. A concomitant increase in CD4 cell numbers, which was sustained over 52 weeks of follow-up and which was also dose related, was observed. This combination therapy deserves further study, particularly as part of triple-drug regimens.
AB - The combination of two nucleoside analogues, didanosine (2',3'- dideoxyinosine or ddI) and stavudine (2',3'-didehydro-2',3'-dideoxythymidine or d4T) was studied in a double-blind dose-ranging trial to provide information about toxicity and efficacy. The 86 patients studied were antiretroviral naive and had pretreatment CD4 cell counts between 200 and 500 cells/mm3. The combination was well tolerated, with no evidence of dose- related side effects and mini- real development of peripheral neuropathy. There was a sustained decrease in human immunodeficiency virus (HIV) viral RNA levels, which appeared greater in patients receiving a full dose of one or both compounds. A concomitant increase in CD4 cell numbers, which was sustained over 52 weeks of follow-up and which was also dose related, was observed. This combination therapy deserves further study, particularly as part of triple-drug regimens.
UR - http://www.scopus.com/inward/record.url?scp=6844255875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=6844255875&partnerID=8YFLogxK
M3 - Article
VL - 2
SP - 89
EP - 93
JO - Antiviral Therapy
JF - Antiviral Therapy
SN - 1359-6535
IS - SUPPL.3
ER -